Federated Hermes Inc. Reduces Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Federated Hermes Inc. lessened its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 47.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 95,827 shares of the company's stock after selling 85,235 shares during the quarter. Federated Hermes Inc.'s holdings in Hims & Hers Health were worth $2,832,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of HIMS. Farallon Capital Management LLC raised its position in Hims & Hers Health by 64,338.5% in the fourth quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock worth $202,556,000 after purchasing an additional 8,364,000 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Hims & Hers Health by 29.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock worth $168,079,000 after buying an additional 1,562,302 shares during the period. Invesco Ltd. boosted its stake in Hims & Hers Health by 613.9% in the 4th quarter. Invesco Ltd. now owns 1,277,026 shares of the company's stock valued at $30,878,000 after buying an additional 1,098,148 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Hims & Hers Health in the fourth quarter valued at $18,048,000. Finally, Yong Rong HK Asset Management Ltd raised its stake in Hims & Hers Health by 41.2% during the first quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company's stock worth $70,920,000 after acquiring an additional 700,100 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Andrew Dudum sold 125,335 shares of the firm's stock in a transaction on Monday, July 21st. The stock was sold at an average price of $49.54, for a total transaction of $6,209,095.90. Following the completion of the transaction, the chief executive officer directly owned 92,313 shares of the company's stock, valued at $4,573,186.02. This trade represents a 57.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Oluyemi Okupe sold 11,581 shares of the firm's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $47.70, for a total transaction of $552,413.70. Following the sale, the chief financial officer directly owned 54,084 shares of the company's stock, valued at approximately $2,579,806.80. This trade represents a 17.64% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 737,704 shares of company stock valued at $40,644,035. 17.71% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on HIMS shares. UBS Group set a $30.00 target price on Hims & Hers Health in a report on Monday, June 23rd. Truist Financial raised their target price on Hims & Hers Health from $45.00 to $48.00 and gave the company a "hold" rating in a research note on Thursday, July 17th. Wall Street Zen downgraded shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research report on Monday, July 28th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Finally, Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $39.83.

Hims & Hers Health Stock Down 7.6%

Shares of NYSE HIMS traded down $4.23 during trading hours on Wednesday, hitting $51.30. The company had a trading volume of 45,990,136 shares, compared to its average volume of 34,446,719. Hims & Hers Health, Inc. has a 1-year low of $13.47 and a 1-year high of $72.98. The firm's 50 day moving average is $53.83 and its 200-day moving average is $44.59. The stock has a market capitalization of $11.48 billion, a P/E ratio of 64.12, a price-to-earnings-growth ratio of 2.34 and a beta of 2.08.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The firm had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a net margin of 9.63% and a return on equity of 27.26%. The business's revenue was up 72.6% on a year-over-year basis. During the same period last year, the business earned $0.06 EPS. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.